Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over

Final draft guidance

Final draft guidance (PDF 219 KB)

Committee papers (PDF 7.59 MB)

Final draft guidance - equality impact assessment (PDF 141 KB)

Public committee slides - ACM1 (briefing) (PDF 440 KB)

Public committee slides - ACM1 (presentation) (PDF 375 KB)

Committee meeting

Final scope (PDF 212 KB)

Final stakeholder list (PDF 158 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 233 KB)

Draft matrix post referral (PDF 160 KB)